mmm-online -- Following a full-scale realignment of its commercial model in 2009, Novartis will make new adjustments to its US pharmaceutical operations, including a change at the top: Ludwig Hantson, CEO and head of North American pharmaceuticals, will exit the company, a Novartis spokeswoman confirmed.
